Paraganglioma Market Report 2026

The paraganglioma market size has grown steadily in recent years. It will grow from $3.02 billion in 2025 to $3.17 billion in 2026 at a compound annual growth rate (CAGR) of 4.7%. The growth in the historic period can be attributed to limited access to ophthalmology specialists, dependence on corticosteroid therapies, lack of advanced diagnostic tools, low awareness of panuveitis complications, fragmented treatment infrastructure.

The paraganglioma market size is expected to see steady growth in the next few years. It will grow to $3.76 billion in 2030 at a compound annual growth rate (CAGR) of 4.4%. The growth in the forecast period can be attributed to advancements in biologic and immunotherapy drugs, increasing prevalence of autoimmune and infectious eye disorders, growth of teleophthalmology and digital monitoring, rising investments in ai-based diagnostics, expansion of hospital and specialty clinic distribution channels. Major trends in the forecast period include rising adoption of biologic and targeted therapies, integration of teleophthalmology and remote monitoring, ai-assisted diagnostic tools for uveitis, growth of personalized eye care solutions, expansion of specialized ophthalmology centers.

The increasing investments in oncology research and medicine are expected to drive the growth of the paraganglioma market going forward. Investments in oncology research and medicine involve financial commitments from governments, pharmaceutical firms, research organizations, and private investors aimed at advancing cancer prevention, diagnosis, and treatment. The rise in these investments is driven by the growing global cancer burden, progress in precision medicine, rising demand for innovative therapies, expansion of clinical trials, increased public and private funding initiatives, and the development of targeted and immunotherapy treatments. These investments support the paraganglioma market by enabling advancements in early diagnosis, improving treatment options such as targeted therapies and immunotherapies, financing clinical trials for more effective drugs, strengthening pediatric cancer care infrastructure, and promoting research to better understand the disease’s biology and progression. For example, in May 2024, IQVIA, an India-based analytics and information technology company, reported that global spending on cancer medicines reached $223 billion in 2023, reflecting a $25 billion increase from 2022, and is projected to rise to $409 billion by 2028. Therefore, the growth in investments in oncology research and medicine is fueling the paraganglioma market.

Growing focus on personalized medicine approaches is expected to propel the growth of the paraganglioma market going forward. Personalized medicine involves customizing treatment and monitoring strategies based on an individual’s genetic, molecular, or clinical characteristics. Interest in personalized medicine is increasing because it allows therapies to be tailored to a patient’s genetic profile, enhancing treatment effectiveness while minimizing adverse effects. Paraganglioma benefits significantly from this approach, as many cases involve germline pathogenic variants in genes such as SDHB, SDHD, RET, and VHL. For instance, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that the FDA approved 16 new personalized treatments for rare disease patients in 2023, up from six approvals in 2022. Of these approvals, seven were cancer-related, while three targeted other diseases and conditions. Therefore, the expanding emphasis on personalized medicine is driving growth in the paraganglioma market.

Companies operating in the paraganglioma market are increasingly focusing on developing advanced therapies such as oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitors to provide targeted treatment options for patients. Oral HIF-2α inhibitors are targeted therapies that suppress HIF-2α activity, a critical driver of tumor growth in low-oxygen environments, thereby helping to slow disease progression in cancers such as paraganglioma. For example, in January 2025, Merck, a US-based biopharmaceutical company, announced that the U.S. Food and Drug Administration granted priority review for a supplemental new drug application for Welireg (belzutifan). The therapy is intended for adult and pediatric patients aged 12 years and older with advanced, unresectable, or metastatic pheochromocytoma and paraganglioma. The application is supported by objective response rate and duration of response data from the Phase 2 LITESPARK-015 trial.

Major companies operating in the paraganglioma market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Mount Sinai, Penn Medicine, Stanford Health Care, St. Jude Children's Research Hospital, UT Health San Antonio, The University of Chicago Medical Center, Fred Hutchinson Cancer Center, Florida Cancer Specialists & Research Institute, Invitae Corp., Clinigen Group plc, Fulgent Genetics, Dana-Farber Cancer Institute Inc., Oncology Hematology Care Inc., Enterome, National Institutes of Health Clinical Center, Progenics Pharmaceuticals Inc., Pheo Para Alliance, Saint John’s Cancer Institute.

North America was the largest region in the paraganglioma market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the paraganglioma market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the paraganglioma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the panuveitis treatment market by increasing costs for imported biologics, immunotherapy agents, and advanced ophthalmic diagnostic tools. Hospital pharmacies, specialty clinics, and home care providers in north america, europe, and asia-pacific are most affected due to import reliance. While tariffs create cost pressures, they also encourage local manufacturing, stimulate innovation in targeted therapies, and strengthen regional supply chain resilience.

The paraganglioma market research report is one of a series of new reports that provides paraganglioma market statistics, including paraganglioma industry global market size, regional shares, competitors with a paraganglioma market share, detailed paraganglioma market segments, market trends and opportunities, and any further data you may need to thrive in the paraganglioma industry. This paraganglioma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Paraganglioma is a rare type of neuroendocrine tumor that arises from paraganglia, which are groups of cells associated with the autonomic nervous system. These tumors are commonly located in the head, neck, chest, or abdomen and may secrete excess hormones, with some carrying a risk of becoming malignant. Early detection plays a critical role in effective treatment and in reducing the likelihood of complications.

The main types of paraganglioma include sympathetic paragangliomas, parasympathetic paragangliomas, carotid paragangliomas, cervical paragangliomas, jugular paragangliomas, secretory paragangliomas, and temporal paragangliomas. Sympathetic paragangliomas are uncommon neuroendocrine tumors that arise within the sympathetic nervous system and frequently secrete catecholamines. These tumors can originate in areas such as the head and neck, abdomen, pelvis, and other regions. Treatment options include peptide receptor radionuclide therapy, surgery, chemotherapy, radiation therapy, and other approaches. These treatments are distributed through hospital pharmacies, drug stores, retail pharmacies, and online pharmacies and are utilized by end users such as hospitals, specialty clinics, cancer research institutes, and others.

The paraganglioma market consists of revenues earned by entities by providing services such as diagnosis & screening services, post-treatment and support services, and clinical trials and research services. The market value includes the value of related goods sold by the service provider or included within the service offering. The paraganglioma market also includes sales of imaging kits, alpha-adrenergic blockers, and supportive care products. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.